Caxton Associates LP Aerie Pharmaceuticals Inc Transaction History

Caxton Associates LP

  • $1.78 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$6.37 - $15.23 $187,647 - $448,645
29,458 Added 93.47%
60,974 $923,000
Q2 2022

Aug 15, 2022
BUY
$4.95 - $9.16 $156,004 - $288,686
31,516 New
31,516 $236,000

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email